Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Lonza plans to increase capacity for highly potent active pharmaceutical ingredients (HPAPIs) by adding two 4 m3 multipurpose production lines at its main site in Visp, Switzerland, by July 2020. The expansion will support a long-term manufacturing agreement with AstraZeneca as well as overall increased HPAPI demand for cancer therapies. “Oncology continues as the leading indication in biopharma,” says Lee Newton, head of Lonza’s API business.
This article has been sent to the following recipient: